Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Launched by BRISTOL-MYERS SQUIBB · Feb 9, 2006
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with previously treated, therapy-refractory or -intolerant, Stage III (unresectable) or Stage IV melanoma
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tucson, Arizona, United States
New York, New York, United States
Orlando, Florida, United States
Greenville, South Carolina, United States
Miami Beach, Florida, United States
Columbia, Missouri, United States
Robbinsdale, Minnesota, United States
West Palm Beach, Florida, United States
Portland, Oregon, United States
Dallas, Texas, United States
St. Louis, Missouri, United States
Cleveland, Ohio, United States
Park Ridge, Illinois, United States
Louisville, Kentucky, United States
Charlotte, North Carolina, United States
New Haven, Connecticut, United States
San Diego, California, United States
Jacksonville, Florida, United States
Heidelberg, Victoria, Australia
Bruxelles, , Belgium
Edmonton, Alberta, Canada
Laverne, California, United States
St Joseph, Missouri, United States
Cincinnati, Ohio, United States
Dallas, Texas, United States
Brussels, , Belgium
Porto Alegre, Rio Grande Do Sul, Brazil
Jau, Sao Paulo, Brazil
Calgary, Alberta, Canada
Olomouc, , Czech Republic
Lyon Cedex 08, , France
Paris, , France
Vandoeuvre Les Nancy, , France
Johannesburg, Gauteng, South Africa
Essen, , Germany
Santa Monica, California, United States
Indianapolis, Indiana, United States
Baltimore, Maryland, United States
Newcastle, New South Wales, Australia
Brisbane, Queensland, Australia
Wodonga, Victoria, Australia
Centro Porto Alegre, Rio Grande Do Sul, Brazil
Sao Paulo, , Brazil
Kingston, Ontario, Canada
Praha, , Czech Republic
Brest, Cedex, France
Clermont Ferrand, , France
Lyon, , France
Marseille Cedex 09, , France
Rennes, , France
Toulouse, , France
Berlin, , Germany
Heidelberg, , Germany
Jena, , Germany
Kiel, , Germany
Mannheim, , Germany
Wurzburg, , Germany
Pécs, , Hungary
Pretoria, Gauteng, South Africa
Cape Town, Western Cape, South Africa
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials